Coeptis Therapeutics Inc. (OTCPK:COEP) agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. (NasdaqCM:STAB) for $6 million on April 6, 2022. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.263 USD | -3.91% | -1.13% | -66.45% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
0.263 USD | -3.91% | -1.13% | 9.53M | ||
0.0006 USD | 0.00% | -14.29% | 43.55K | ||
1st Jan change | Capi. | |
---|---|---|
-66.45% | 9.53M | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+17.64% | 246B | |
+10.71% | 213B | |
-3.31% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- COEP Stock
- News Coeptis Therapeutics Holdings, Inc.
- Coeptis Therapeutics Inc. agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. for $6 million.